5 Long-Term Stocks to Buy During Recessions

In this article, we discuss the 5 long-term stocks to buy during recessions. If you want to read about some more stocks to buy during recessions, go directly to 10 Long-Term Stocks to Buy During Recessions.

5. Pfizer Inc. (NYSE:PFE)

Number of Hedge Fund Holders: 70    

Pfizer Inc. (NYSE:PFE) discovers, develops, manufactures, and sells biopharmaceutical products. In mid-September, the company announced that it had begun trials of an mRNA-based influenza vaccine. Initially, the firm said that first participants were dosed in a phase 3 of quadrivalent modified RNA influenza vaccine in some 25,000 healthy US adults that were aged 18 years and older. Pfizer has the exclusive right to carry out development and commercialization of mRNA-based influenza vaccines under a deal with BioNTech. 

On August 1, investment advisory Barclays maintained an Equal Weight rating on Pfizer Inc. (NYSE:PFE) stock and raised the price target to $52 from $50. Analyst Carter Gould issued the ratings update. 

At the end of the second quarter of 2022, 70 hedge funds in the database of Insider Monkey held stakes worth $2.8 billion in Pfizer Inc. (NYSE:PFE), compared to 79 in the preceding quarter worth $4.1 billion. 

In its Q4 2021 investor letter, ClearBridge Investments, an asset management firm, highlighted a few stocks and Pfizer Inc. (NYSE:PFE) was one of them. Here is what the fund said:

“While the level of general turnover abated as we progressed through 2021, it remained high in one area: post-COVID-19 recovery plays. The concept behind this investment thesis was, and still is, straightforward: with the advent of effective vaccines, the path from pandemic to endemic is just a matter of time. As this transition occurs, the estimated excess savings of over $2 trillion built up on U.S. consumer balance sheets will unlock dramatic pent-up demand for experiences, especially global travel. This investment case seemed especially compelling when the Pfizer Inc. (NYSE:PFE) vaccine positively surprised markets in November 2020. As a result, we made post-COVID-19 stocks (which were trading well below our estimate of recovery value) a sizable theme within the portfolio. We understood this to be a more aggressive tilt in positioning because it required a major improvement in demand to catalyze fundamentals and drive price toward higher business values. (…read more)